List view / Grid view
3 February 2016 | By Victoria White
XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumours, including breast, gastric and non-small cell lung cancers...
3 February 2016 | By Victoria White
A new ‘roadmap’ document published today outlines how The London Cancer Hub will become a world-leading life-science campus...
3 February 2016 | By Victoria White
AbCellera will apply its high-throughput single cell antibody platform for the discovery of the rare monoclonal antibodies...
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
3 February 2016 | By Victoria White
This award will give Dr Echalier access to the drug discovery capabilities of Domainex in support of her research...
2 February 2016 | By Victoria White
The £60 million enables the company to maximise the potential of its DUB platform and advance a series of DUB inhibitors...
2 February 2016 | By Victoria White
A team of scientists from Bath, Cambridge and the USA has identified a piece of non-coding RNA that stops cells turning cancerous...
2 February 2016 | By Victoria White
The Cell Therapy Catapult has changed its name to the Cell and Gene Therapy Catapult to more accurately reflect the activities of the organisation...
1 February 2016 | By Victoria White
The aim of the research is to understand the genes human embryos need to develop successfully...
1 February 2016 | By Victoria White
Scientists have, for the first time, identified and isolated stem cells capable of skull formation and craniofacial bone repair in mice...
1 February 2016 | By Victoria White
Astellas and CLINO have entered into a license agreement for the worldwide development and commercialisation of Adeno-associated Virus-modified Volvox channelrhodopsin-1 (AAV-mVChR1)...
1 February 2016 | By Victoria White
Nordic Nanovector has been awarded the NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme...
29 January 2016 | By Victoria White
Researchers have identified the cells that likely give rise to the brain tumour subtype Group 4 medulloblastoma, removing a barrier to developing more effective targeted therapies....
29 January 2016 | By SMi Group
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference...
29 January 2016 | By SMi Group
Registration now live for the 5th annual ADC Summit taking place at the Holiday Inn Kensington Forum, London, UK on the 23rd – 24th May 2016...
